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In metazoans, TOR is an essential pro-tein that functions as a master regula-
tor of cellular growth and proliferation. 
Over the past decade, there has been an 
explosion of information about this criti-
cal master kinase, ranging from the com-
position of the TOR protein complex to 
its ability to act as an integrator of numer-
ous extracellular signals. Unfortunately, 
this plethora of information has also 
raised numerous questions regarding 
TOR function. Currently, the prevailing 
view is that mammalian TOR (mTOR) 
exists in at least two molecular com-
plexes, mTORC1 and mTORC2, which 
are largely defined by the presence of 
either RAPTOR or RICTOR. However, 
additional co-factors have been identi-
fied for each complex, and their impor-
tance in mediating mTOR signals has 
been incompletely elucidated. Similarly, 
there are differences in mTOR function 
that reflect the tissue of origin. In this 
review, we present an alternative view 
to mTOR complex formation and func-
tion, which envisions mTOR regulation 
and signal propagation as a reflection of 
cell type- and basal state-dependent con-
ditions. The re-interpretation of mTOR 
biology in this framework may facilitate 
the design of therapies most likely to 
effectively inhibit this central regulator 
of cell behavior.
Introduction
The mammalian target of rapamycin 
(mTOR) is one of the most studied signal-
ing complexes, whose deregulated func-
tion leads to a variety of human disorders, 
ranging from cancer and immune dysfunc-
tion to autism and epilepsy.1-5 The function 
of this signaling complex is particularly 
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relevant to nervous system biology. As a 
regulator of protein translation in nerve 
cells (neurons), mTOR signaling controls 
synaptic plasticity by modulating long-
term potentiation (LTP) and long-term 
depression (LTD), important for memory 
and learning.6-9 Additionally, in the hypo-
thalamus, mTOR regulates food intake 
and controls hormone production relevant 
to the onset of puberty.10,11 In neurons, 
mTOR regulates axonal regeneration in 
response to nerve injury,12-14 while in glial 
cells, it functions to limit astrocytic scar 
formation in the brain and spinal cord.15,16 
Similarly, mTOR signaling is affected in a 
number of neurodegenerative conditions, 
including Alzheimer disease, Parkinson 
disease, stroke and Huntington disease, 
such that pharmacologic inhibition of 
mTOR activity can reduce cognitive 
defects associated with these conditions 
in mice.17-21 In other conditions, abnormal 
mTOR signaling has been implicated in 
the genesis of recurrent seizures, where it 
controls mossy fiber sprouting in the hip-
pocampus.22-24 Finally, recent studies have 
suggested that deregulated mTOR activa-
tion might underlie autistic-like behaviors 
in rodents.25 Together, these observations 
highlight the essential role of mTOR in 
maintaining nervous system homeostasis 
both in health and in disease.
The critical importance of mTOR 
to nervous system function derives from 
studies of inherited cancer predisposi-
tion syndromes in which mutations in 
upstream regulators of mTOR result in 
mTOR hyperactivation (Fig. 1). These 
conditions include neurofibromatosis 
type 1 (NF1) and tuberous sclerosis com-
plex (TSC). NF1 is a common autoso-
mal dominant disorder in which affected 
children and adults are prone to the 
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genetically engineered mice with rapamy-
cin to inhibit mTOR activity leads to 
reduced seizure frequency and severity.43 
Moreover, clinical trials using rapamycin 
analogs have demonstrated efficacy in the 
treatment of SEGAs in individuals with 
TSC.44-46
Other inherited syndromes that do 
not affect the nervous system have also 
provided insights into the role of mTOR 
signaling in normal growth control. 
Germline mutations in the PTEN tumor 
suppressor gene result in a variety of 
clinical conditions, including Cowden 
syndrome, Proteus syndrome, autism 
spectrum disorder (ASD) and Lhermitte-
Duclos disease.47-51 In each of these syn-
dromes, mutational inactivation of the 
PTEN gene leads to deregulated AKT sig-
naling and increased mTOR activation. In 
genetically engineered mice, Pten inactiva-
tion in neuroglial cells results in progres-
sive seizures, which can be dramatically 
attenuated with rapamycin analog treat-
ment.52-54 Moreover, these Pten conditional 
knockout mice exhibit abnormal social 
for nerve sheath tumors and gliomas in 
individuals with NF1.
Individuals with TSC are prone to the 
development of brain tumors (subepen-
dymal giant cell astrocytomas, SEGAs), 
intractable epilepsy, autism and men-
tal retardation.33,34 In addition, affected 
individuals develop renal, heart and lung 
tumors, especially pulmonary lymphan-
gioleiomyomatosis (LAM).35 In contrast 
to NF1, mutations in one of two genetic 
loci (TSC1 or TSC2) underlie the patho-
genesis of TSC.36,37 However, individu-
als with TSC harbor mutations in either 
the TSC1 or TSC2 gene, not both. The 
TSC1 gene encodes hamartin, which 
forms a regulatory complex with the 
TSC2 protein tuberin to negatively regu-
late the activity of a related RAS protein, 
termed RAS homolog expressed in brain 
(RHEB).38-43 Bi-allelic inactivation of 
the TSC1 or TSC2 gene leads to loss of 
function of the tuberin-hamartin com-
plex and results in increased RHEB acti-
vation and mTOR hyperactivation (see 
below). Similar to NF1, treatment of Tsc 
development of peripheral nerve sheath 
tumors (neurofibromas), brain tumors 
(optic gliomas), learning disabilities and 
attention deficit.26 The NF1 gene is a clas-
sic tumor suppressor gene, such that bi-
allelic NF1 gene inactivation is required 
for tumorigenesis. The NF1 protein, neu-
rofibromin, functions in part as a negative 
regulator of the RAS proto-oncogene and 
serves to accelerate the conversion of active 
GTP-bound RAS to inactive GDP-bound 
RAS by virtue of the GTPase-activating 
protein (GAP) domain.27 Loss of neurofi-
bromin expression in astrocytes or neural 
stem cells in the brain results in increased 
RAS activation, and leads to high levels of 
activated AKT and MEK signaling, which 
converge on the mTOR complex to regu-
late cell growth.27-29 In this respect, inhibi-
tion of mTOR hyperactivation using the 
macrolide rapamycin inhibits the growth 
of malignant peripheral nerve sheath 
tumors and optic gliomas in genetically 
engineered mice.30-32 These exciting pre-
clinical observations have leveraged the 
design and execution of new clinical trials 
Figure 1. Current model of mtOr regulation. the mtOr complex is regulated by numerous upstream kinase molecules. Neurofibromin (Nf1 gene 
product) loss leads to increased raS activity, leading to aKt-mediated phosphorylation of PraS40 and release of PraS40-mediated mtOr inhibi-
tion. in addition, the increased raS activity in Nf1-deficient cells leads to MeK activation, which phosphorylates tuberin (tSC complex), and increased 
rheb-mediated mtOr activation. Lastly, LKB1 activates aMPK, which inhibits tSC complex function, such that loss of function mutations in LKB1 lead 
to increased rheb-mediated mtOr activation.
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eIF4E, resulting in continued transla-
tional repression and securing 4EBP1 as a 
downstream substrate of mTOR.83
In recent years, a distinction has 
been made between mTOR complexes 
based on their sensitivity to rapamycin 
treatment (Fig. 3). mTOR complex 1 
(mTORC1) is sensitive to rapamycin 
and consists of RAPTOR, PRAS40, 
mLST8 and DEPTOR proteins.73,84 
Rapamycin binds to FKBP12, such that 
the rapamycin-FKBP12 complex inhibits 
RAPTOR-bound mTOR. mTOR com-
plex 2 (mTORC2) is relatively insensitive 
to rapamycin and consists of RICTOR, 
PROTOR, DEPTOR, mLST8 and 
mSIN1.85 However, prolonged treatment 
with rapamycin can inhibit mTORC2, 
most likely due to the progressive seques-
tration of pools of mTOR by rapamy-
cin-FKBP12. This model predicts that 
overproduction of mTOR would restore 
mTORC2 assembly and activation in 
the prolonged presence of rapamycin, 
although this has not formally been tested.
While the individual proteins of the 
mTOR complexes and their precise func-
tions are hotly debated, several key players 
have been identified through loss-of-func-
tion studies. Depletion of RAPTOR in 
mammalian cells results in decreased 
cell size and lower levels of phosphory-
lated S6K-1, demonstrating a crucial 
role for RAPTOR in mTOR signaling.73 
Moreover, non-ionic detergent treatment 
of mTORC1 complexes release RAPTOR 
from mTOR, resulting in markedly atten-
uated mTOR activity and a lack of 4EBP1 
phosphorylation.84 Similarly, depletion of 
mLST8 results in decreased cell size and 
lower S6K-1 phosphorylation, establish-
ing mLST8 as an integral component of 
mTORC1.86 Of note, mLST8 binds to 
the kinase domain of mTOR and facili-
tates enhanced binding of RAPTOR to 
mTOR. These findings further support 
an integral function of mLST8 in mTOR 
firmly establishing the products of these 
genes as the bona fide rapamycin targets.62 
Whereas deletion of Tor1 in yeast results in 
decreased cell proliferation but not lethal-
ity, TOR deletion in metazoans is lethal. 
Genetic studies in Drosophila melanogaster 
first revealed the role of dTOR in regulat-
ing cell size; dTor-deficient flies exhibit a 
cell autonomous decrease in both cell size 
and proliferation.71,72 Mammalian TOR 
(mTOR) is ubiquitously expressed in tis-
sues, with highest levels of expression in 
the brain and skeletal muscle.73 Consistent 
with this pattern of expression, condi-
tional deletion of mTOR in muscle results 
in decreased muscle mass, muscle dystro-
phy and decreased oxidative capacity.74
The use of rapamycin has been a valu-
able tool for identifying molecular tar-
gets downstream of mTOR. While many 
proteins have been elucidated using this 
strategy, S6K-1 and 4EBP1 are the best-
characterized molecules. S6K-1 phosphor-
ylates the ribosomal protein S6 (rpS6).75,76 
Rapamycin treatment inhibits S6K-1 
activity and, thus, reduces rpS6 phos-
phorylation in multiple cell types under 
varying stimuli.77,78 In flies, overexpression 
of dS6K rescues the growth phenotype of 
dTOR deficiency, indicating that S6K is a 
critical downstream effector of dTOR in 
cell size determination.79 Moreover, S6k1-
knockout mice are considerably smaller 
than their wild-type littermates, further 
stressing the importance of S6K activity 
in mediating cell growth and size.80
4EBP1 is a potent translational repres-
sor, binding tightly to the eIF4E mRNA 
cap-binding protein. Through its interac-
tion with eIF4E, 4EBP1 effectively com-
petes with eIF4G, preventing its access to 
eIF4E. Stimulation of mTOR signaling 
results in 4EBP1 phosphorylation and 
eIF4E release, allowing eIF4E to bind to 
eIF4G and initiate cap-dependent mRNA 
translation.81,82 Treatment with rapamycin 
prevents the dissociation of 4EBP1 from 
interactions and exaggerated responses to 
sensory stimuli, which are also suppressed 
by pharmacologic mTOR inhibition.25 In 
addition, mutations in the LKB1 gene are 
responsible for Peutz-Jeghers syndrome, a 
disorder of intestinal polyp formation.55 
LKB1 is a serine/threonine kinase that 
activates 5'AMP-activated protein kinase 
(AMPK) by phosphorylation to inhibit 
tuberin function.56-58 Mutational inactiva-
tion of the LKB1 gene results in mTOR 
hyperactivation under low energy condi-
tions and underlies the propensity for 
tumor formation in conditional knockout 
mouse strains.59,60
In this Extra View, we will review the 
current understanding of mTOR regula-
tion and signaling, discuss emerging and 
unresolved controversies in mTOR biol-
ogy and propose a new conceptual model 
for mTOR function.
Current Concept of mTOR  
and its Complexes
Although cell growth, an increase in cell 
mass and size through macromolecu-
lar synthesis, is distinct from cell cycle 
progression and division, these two pro-
cesses are generally tightly regulated. 
In eukaryotic systems, mTOR is a key 
regulator of cell mass and size, identified 
through the elucidation of the target of 
an antifungal agent, rapamycin.61 Using 
genetic screens, the intracellular rapamy-
cin receptor FKBP12 and TOR were dis-
covered.62-65 Eukaryotic TORs are large 
proteins (~280 kDa) that exhibit 40–60% 
sequence homology at the amino acid 
level and are members of the phosphati-
dylinositol-3-kinase-related protein kinase 
(PIKK) family (Fig. 2).66-68 Unlike PI3K, 
which possesses lipid kinase activity, TOR 
functions solely as a protein kinase.69,70 In 
Saccharomyces cerevisiae, mutations in Fpr1 
(gene encoding FKBP12) or Tor1 allow 
for growth in the presence of rapamycin, 
Figure 2. anatomy of the mtOr protein. the mtOr protein is composed of several domains, including a Heat (Huntington, eF3a, atM, tOr), Fat 
(FraP, atM, ttraP), r (tOr), FatC (FraP, atM, trraP C-terminal) and kinase domain. the amino acid residues are shown along the bottom.
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scrutiny. Many of these studies were per-
formed in fibroblasts or established cell 
lines, where components may not be uni-
formly expressed or functional. Recent 
studies suggest that mTOR regulation of 
brain cell function may not follow these 
rules (see below). These new findings sug-
gest that some of the existing dogma may 
need to be reassessed.
Upstream Regulation  
of mTOR Activation
Nutrients, energy, stress and growth 
factors are the major upstream signal-
ing inputs for the mTORC1 complex 
(Fig. 4). While the varying flux of sig-
nals from each of these pathways coop-
erates to activate mTOR, we will discuss 
each component separately. Amino acids 
are the building blocks of proteins and 
can be used in the synthesis of nucleic 
acids and ATP. The RAG family of small 
GTPases serves as the link between intra-
cellular amino acids and mTORC1.94,95 
RAG proteins form heterodimers of 
RAGA or RAGB with either RAGC or 
RAGD. In the absence of amino acids, 
RAG complexes are inactive, and RAGA 
and RAGB are bound to GDP. The pres-
ence of amino acids activates RAGA and 
RAGB and switches them to GTP-bound 
proteins that interact with RAPTOR. 
This interaction causes mTORC1 to re-
localize to the surface of endosomes and 
lysosomes, enabling mTORC1 to interact 
mTOR complexes.90 PRAS40 binds to 
the kinase domain of mTOR, although 
its interaction does not release mLST8. 
Additionally, PRAS40 is phosphorylated 
by activated AKT, and this phosphoryla-
tion results in the either the full release or 
lessened affinity of PRAS40 for mTOR 
through the formation of PRAS40 and 
14-3-3 protein complexes.90,91 DEPTOR 
was discovered following immunoprecipi-
tation of RAPTOR and RICTOR pro-
teins. Knockdown of DEPTOR results in 
the activation of both mTORC1 and 2, 
implying that it is a negative regula-
tor of both complexes.92 However, over-
expression of DEPTOR only inhibits 
mTORC1; mTORC2 activity is elevated 
upon DEPTOR overexpression. While it 
is unclear how this asymmetrical signaling 
is achieved, it is clear that mTORC1 and 2 
both phosphorylate DEPTOR, signaling 
for its destruction by the SCF (βTrCP) E3 
ligase.93
To date, the evidence for two distinct 
mTOR complexes is largely based on the 
identification of independent RAPTOR- 
and RICTOR-containing immunopre-
cipitates with mTOR. Clearly, RAPTOR 
and RICTOR are not found in immu-
noprecipitates of the other protein, and 
RICTOR appears to interact with pro-
teins unique to its complex (mSIN1 and 
PROTOR). However, the finding of mul-
tiple mSIN1 isoforms pertaining to multi-
ple mTORC2s suggests that a simple view 
of two complexes may warrant further 
activation through its ability to bind to 
mTOR.
RICTOR was discovered in mTOR 
immunoprecipitates and shares sig-
nificant regions of homology with the 
Avo3p rapamycin-insensitive protein 
from S. cerevisiae. RICTOR is found 
in distinct mTOR complexes devoid of 
RAPTOR and is unable to bind FKBP12-
rapamycin.85 RICTOR-bound mTOR 
contains mLST8, but these complexes are 
unable to phosphorylate S6K-1. Instead, 
RICTOR-mTOR-mLST8 complexes 
modulate the phosphorylation of PCKα 
and AKT.87 Further studies of mTORC2 
identified mSIN1 as a necessary protein 
in the assembly of mTORC2. mSIN1 
exists as multiple isoforms, with at least 
three of these isoforms establishing 
unique mTORC2 complexes, each being 
regulated by different upstream stimuli.88 
Moreover, mSIN1 mediates the interac-
tion of SGK-1 with mTORC2, suggest-
ing that it might serve as a scaffold for 
downstream mTOR substrates. PROTOR 
(1 and 2) was recently added to the list of 
mTORC2-specific-interacting proteins. 
However, knockdown of PROTOR-1 does 
not affect mTORC2 complex formation 
or activity, suggesting that PROTOR-1 is 
not an essential mTORC2 component.89
mTOR complexes are controlled 
by a set of negative regulators, includ-
ing PRAS40 and DEPTOR. PRAS40 
was first identified as an mTOR-inter-
acting protein by mass spectrometry of 
Figure 3. mtOr complexes. mtOr is composed of two distinct complexes, mtOrC1 and mtOrC2. tOrC1 is composed of mLSt8, raPtOr, DePtOr and 
PraS40, while the mtOrC2 complex is composed of mSiN1, mLSt8, riCtOr and DePtOr. mtOrC1 signals to S6K1, 4eBP1 and irS1, whereas mtOrC2 
activates aKt, SGK1 and PKCα.
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The latter is achieved through the p53 
transcriptional induction of SESTRIN1 
and SESTRIN2, which are both potent 
activators of AMPK.109 Thus, AMPK is 
positioned as a central cellular stress relay 
kinase to mTORC1.
Of note, little is known about the 
upstream activating signals for mTORC2. 
While it is appreciated that mTORC2 
is largely activated by growth factors,110 
its ability to signal in any specific man-
ner seems improbable given the plethora 
of potential upstream signals. This is 
further highlighted by the divergence 
of AKT, SGK and PKCα regulation by 
mTORC2 in response to various growth 
factors. Thus, mTORC2 must somehow 
be capable of distinguishing between 
growth factor inputs to elicit the proper 
downstream kinase activation. Our earlier 
discussion of mSIN1 isoforms might pro-
vide some clues to this achieved diversity 
of mTORC2, but it seems more likely that 
other, as-yet-unidentified mechanisms 
PRAS40 from the complex, thus establish-
ing that upstream (by AKT) and down-
stream (by mTORC1) phosphorylation of 
PRAS40 are fully activated mTORC1.104
Given the importance of mTORC1 
in controlling ribosome biogenesis and 
mRNA translation, both of which require 
massive amounts of cellular energy, it is 
appropriate that mTORC1 acts as a sen-
sor of energy and stress. In the absence 
of nutrients, cellular ATP levels rapidly 
decline due to altered mitochondrial 
respiration and glycolysis and trigger 
the AMP-activated kinase (AMPK). 
Under increased levels of AMP, AMPK 
phosphorylates TSC2 to activate its 
GAP activity toward RHEB and inac-
tivate mTOR.56,105 Additionally, AMPK 
phosphorylates RAPTOR, leading to 
RAPTOR-14-3-3 binding and allosteric 
inhibition of mTORC1.106 AMPK is capa-
ble of relaying signals from both energy 
stress, such as hypoxia,107 as well as other 
cellular stresses, such as DNA damage.108 
with another small GTPase, Ras homolo-
gous enriched in brain (RHEB).94,96 GDP-
loaded RHEB is unable to interact with 
mTORC1. However, upon growth factor 
stimulation, AKT phosphorylates and 
inactivates tuberin (TSC2 protein),97-99 
which, together with its binding part-
ner hamartin (TSC1 protein), acts as a 
GTPase-activating protein (GAP) for 
RHEB.38,39,41,43 In this manner, TSC1-
TSC2 complexes are potent inhibitors of 
mTORC1 activity. Release of hamartin/
tuberin complex negative regulation of 
RHEB results in increased RHEB GTP-
loading, which, in turn, stimulates mTOR 
kinase activity. Overexpression of RHEB 
maintains mTORC1 activity even in 
the absence of nutrients and growth fac-
tors,38,39,41,100 demonstrating its central role 
in activating mTORC1.
Previous studies using established cell 
lines support a model in which the pri-
mary mode of mTOR activation involves 
TSC-RHEB signaling. In these studies, 
several signaling intermediates (AMPK, 
MEK and AKT) regulate mTOR activity 
by phosphorylating tuberin on a number 
of residues to result in RHEB-mediated 
mTOR activation.39,98,101 For example, 
mTOR hyperactivation and increased 
tumor cell line growth was inhibited when 
an interfering tuberin phospho-mutant 
protein was introduced.97,98 One possible 
exception to this route of mTOR activa-
tion involves PRAS40-mediated mTOR 
regulation. PRAS40 was initially shown 
to operate upstream of mTOR, such that 
AKT phosphorylation of PRAS40 relieved 
TORC1 suppression.90,91 However, more 
recent studies suggest that PRAS40 may 
also be a downstream target of mTORC1 
activity.102,103 Knockdown of PRAS40 
results in a reduction in RAPTOR bound 
to mTOR and attenuated mTORC1 
activity, suggesting that PRAS40 might 
positively regulate the assembly or stabi-
lization of mTORC1.102 This would be 
consistent with dual roles for PRAS40 in 
negatively regulating the short-term activ-
ity of mTORC1 while enhancing the long-
term stability of mTORC1. Analysis of the 
AKT phosphorylation site (Thr-246) and 
one of the three mTOR phosphorylation 
sites (Ser-221) revealed their concerted 
importance in promoting 14-3-3 bind-
ing for PRAS40, which helps to remove 
Figure 4. mtOr functions as a molecular integrator. various inputs to mtOr provide information 
about amino acid availability, growth factor mitogenic signaling, oxidative damage and oxygen 
levels. this information mus  be integrated by mtOr through the use of its binding partners to 
provide meaningful outputs that dictate mrNa transcription, protein translation, cell growth, cell 
survival, ribosomal biogenesis and autophagy.
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phosphorylation, 40S ribosome subunits 
(newly produced by S6K-1 signals) would 
not engage the cap complex of eIF4E, 
eIF4G and eIF4A to enable the beginning 
of mRNA scanning. The eIF4G protein 
is also a direct target of S6K-1. Mitogen 
signaling induces phosphorylation of Ser-
422 in a rapamycin-sensitive and S6K-
1-dependent manner.119 A Ser422Ala 
mutant mimicking non-phosphorylated 
eIF4G is unable to stimulate cap-depen-
dent translation,119 and RNAi knockdown 
of eIF4G leads to polysome reduction and 
translational repression of key proteins 
involved in cell survival and prolifera-
tion.120 Additionally, S6K-1 phosphory-
lates and inactivates the programmed cell 
death 4 protein (PCD4). Phosphorylation 
and rescued by proteins downstream of 
mTORC1. First, active S6K-1 stimulates 
the translation of mRNAs containing 
unique 5'-terminal oligopyrimidine tracts 
(TOPs).112,113 TOP-containing mRNAs 
encode ribosomal proteins, elongation 
factors and other critical components of 
ribosome production.114 However, S6K-1 
activity is not obligatory for this important 
process; cells lacking S6K-1 still actively 
translate TOP mRNAs in response to 
growth factor stimulation through a 
potentially redundant mechanism that 
does not involve the phosphorylation of 
rpS6.113,115
Second, phosphorylation of 4EBP1 by 
mTORC1 signals the onset of cap-depen-
dent translation.116-118 Without 4EBP1 
must be in place to provide this diversity 
in mTORC2 signaling.
Downstream mTOR Signaling
After dealing with such a diverse array 
of input signals, both mTORC1 and 
mTORC2 must direct a signaling pro-
gram that leads to the activation of critical 
cellular processes.111 In this regard, it has 
been easier to establish consequences of 
mTORC signaling than to determine the 
underlying intricate mechanisms of how 
the mTOR complex performs these deci-
sions. As such, the hallmark of mTORC1 
activity is the stimulation of ribosome bio-
genesis and mRNA translation (Fig. 5). 
Both processes are inhibited by rapamycin 
Figure 5. Control of translation by mtOrC1 and mtOrC2. mtOrC1 controls cap-dependent translation through the phosphorylation and inactivation 
of 4eBP1, freeing eiF4e to bind to the 7-methylguanosine (m7G) cap structure at the 5' end of mature mrNas. S6K-1 phosphorylates eiF4G to initiate 
its interaction with eiF4G at the cap while also inactivating PCD4, the negative regulator of the eiF4a rNa helicase. mtOrC1 (in astrocytes) and S6K-1 
(in fibroblasts) stimulates the increased expression of nucleophosmin (NPM), which acts in a rate-limiting manner to transport mature 40S and 60S 
ribosome subunits from the nucleolus/nucleus into the cytosol, where they engage in mrNa translation. mtOrC2 interacts with rpL23 and rpL26 of 
the 60S subunit on polysomes during translational elongation. inhibition of mtOrC1 or mtOrC2 dramatically attenuates mrNa translation.
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and aid in their transport into the cytosol, 
placing NPM as a critical nucleolar sensor 
of mTOR signals127,128 (Fig. 5). Moreover, 
actin cytoskeleton rearrangement and 
enhanced proliferation of Nf1-deficient 
astrocytes is dependent on elevated NPM 
expression and its ability to properly trans-
port ribosomes to the cytosol.129
Only recently have we begun to 
appreciate the complexity of down-
stream mTORC2 signaling. Nonetheless, 
mTORC2 activation of AKT, SGK1 and 
PKCα appears to place mTORC2 as the 
effector of numerous and diverse biological 
processes. AKT itself possesses pleiotropic 
biogenesis.123 Indeed, one of the major 
targets of mTORC1 signaling is the 
nucleophosmin (NPM) proto-oncogene, 
a TOP-containing mRNA. Growth sig-
nals, such as those emanating from RAS, 
stimulate the translation of existing 
NPM mRNAs in a rapamycin-sensitive 
mechanism124 through the binding of far 
upstream binding protein-1 (FUBP-1) to 
the 3' untranslated region (UTR) of NPM 
mRNA.125 In agreement with this finding, 
astrocytes lacking Nf1 express elevated 
NPM protein levels and exhibit enhanced 
protein synthesis.126 NPM proteins engage 
assembling ribosomes in the nucleolus 
of PCD4 on Ser67 prevents its association 
with eIF4A and signals the destruction 
of PCD4 by β-Trap.121 Released eIF4A 
then interacts with active eIF4G to ini-
tiate translation.122 This clearly places 
S6K-1 as a central kinase in the activa-
tion of the cap-dependent pre-initiation 
complex. Moreover, mTORC1 provides 
the key signals to both produce ribosomes 
and to enable those ribosomes to engage in 
mRNA translation in response to appro-
priate nutrient, energy and growth signals.
In addition to directly target-
ing the translational machinery, 
mTORC1 indirectly enhances ribosome 
Figure 6. mtOr signaling in the brain does not follow the established canonical rules. (a) in astrocytes, neurofibromin negatively regulates mtOr 
through raS/aKt-mediated signaling. Loss of neurofibromin leads to increased mtOr activation, which results in rac1 and Stat3 activation through 
raPtOr. (B) while tuberin phosphorylation results in loss of tSC complex function and increased rHeB-mediated mtOr activation, NF1 protein 
(neurofibromin) and PteN loss in astrocytes leads to aKt-dependent mtOr activation, which does not involve tSC complex regulation. Moreover, Tsc1/
Tsc2 inactivation or rheb overexpression in vitro or in vivo does not recapitulate the effects of Nf1 or Pten loss on astrocyte growth or gliomagenesis 
in genetically engineered mice. (C) mtOr-regulated aKt activation in neural stem cells (NSCs) following Nf1 gene loss is controlled by the levels of 
raPtOr and riCtOr. NSCs from the cortex fail to activate aKt and increase their proliferation following Nf1 loss, whereas those from the brainstem 
activate aKt and exhibit increased proliferation. this region-specific difference reflects the relative abundance of raPtOr and riCtOr in NSCs from 
these two brain regions.
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mRNA translation as mTORC1 (Fig. 5). 
Indeed, consistent with this notion, cells 
disrupted for mTORC2 function exhibit 
more severely attenuated translation com-
pared with those treated with rapamy-
cin,138 forcing a reassessment of what was 
once thought of as an mTORC1-specific 
function.
Heterogeneity in mTOR Function
The canonical view of mTOR signaling 
envisions the presence of two static com-
plexes with a unique set of associated pro-
teins that collectively signal to a distinct 
set of downstream effectors (Fig. 6). The 
notion that all cells harbor the same col-
lection of static complexes with limited 
hard-wired signaling effector pathways 
has recently been called into question by 
several new observations in brain cells 
(astrocytes and neural stem cells). Using a 
high throughput chemical library screen-
ing approach, we identified STAT3 as a 
downstream effector of Ras/mTOR sig-
naling in Nf1-deficient astrocytes.141 In 
these astrocytes, STAT3 activation was 
inhibited by rapamycin (Fig. 6A). mTOR-
mediated STAT3 regulation involved 
Rac1 activation,129 which resides upstream 
of both mTORC1 and mTORC2.142 
However, astrocytes express very low lev-
els of RICTOR, and STAT3 regulation 
was instead RAPTOR-dependent. These 
findings raise the intriguing possibility 
that the previously rigid signaling dia-
grams might not fully represent the true 
nature of mTOR signaling complexity in 
primary cells or tissues. Furthermore, it 
is also possible that different tissues have 
differing levels of mTOR components, 
which could determine exactly how the 
mTOR complex signals in any given tissue 
(Gutmann DH and Weber JD, unpub-
lished observations).
Compared with other tissues,143-145 the 
biological effects of mTOR activation 
resulting from Pten loss, Nf1 loss, Tsc1 loss 
and RHEB overexpression in astrocytes 
are distinct28 (Fig. 6B). In these experi-
ments, Tsc1 loss and RHEB overexpression 
did not increase astrocyte proliferation in 
vitro, whereas Pten and Nf1 loss led to 
increased cell growth. In all four groups 
of genetically modified astrocytes, mTOR 
activation, as measured by ribosomal S6 
serum, implicating mTORC2 in cytoskel-
eton regulation.85 Moreover, RICTOR 
knockdown also decreased RAC1 activa-
tion, further linking mTORC2 to RHO-
type GTPase control of the cytoskeleton 
and cellular motility.136 Importantly, this 
process is not inhibited by rapamy-
cin, squarely placing mTORC2 as a 
central mediator of cell migration and 
metastasis.136,137
While mTORC1 has been ascribed a 
primary role in regulating mRNA trans-
lation, recent evidence also points to 
mTORC2 as a key player in this process. 
mTORC2 has been isolated in polysomes, 
where it readily associated with individual 
ribosomal proteins of the 60S large sub-
unit, including rpL23a and rpL26.138,139 
Moreover, SIN1 associated with poly(rC) 
binding protein 2 (PCBP2) and RNA 
binding protein, which controls mRNA 
stability and translation in response 
to various cellular stresses.140 Thus, it 
appears that mTORC2 is as connected to 
cellular effects, regulating such events as 
metabolism, survival and proliferation. 
While many AKT substrates remain to be 
uncovered, GSK3β and FOXO1/3A are 
well-studied targets of AKT, controlling 
many of the processes previously ascribed 
to mTORC2. PROTOR-1 serves as an 
adaptor for the phosphorylation of SGK1 
by mTORC2; cells lacking PROTOR fail 
to activate SGK1.130 SGK1 is also regu-
lated by osmotic stress, and its activation 
corresponds with increased epithelial 
sodium channel-dependent Na+ trans-
port.131,132 In glioma cell lines, increased 
RICTOR levels and higher mTORC2 
activity enhanced cellular motility and 
correlated with increased PKCα activity.133 
Although it is unclear how mTORC2 pre-
cisely regulates changes in the actin cyto-
skeleton, PKCα has been implicated in 
this function.134,135 Additionally, knock-
down of mTOR, mLST8 and RICTOR, 
but not RAPTOR, leads to severe defects 
in actin reorganization in the presence of 
Figure 7. mtOrC1 and mtOrC2 integrate multiple inputs and stimulate numerous effectors. 
Seven major categories of inputs signal to mtOr complexes. their combined inputs are viewed as 
aggregate signaling flux that is ultimately interpreted by both mtOrC1 and mtOrC2. the dynam-
ics of this interpretation most likely involve changes in the protein expression level of positive 
(black) and negative (red) regulators of mtOr kinase activity, post-translational modification of 
mtOrC members, binding of complexes to downstream effectors or, most likely, a combination 
of all of these. mtOr complexes then activate downstream signaling effectors based on their in-
terpretation of the aggregate signaling flux flowing into mtOrC1 and mtOrC2. the 4eBP1, S6K-1, 
irS1, aKt, SGK1 and PKCα effectors coalesce to illicit the proper cellular biology (e.g., ribosome 
biogenesis, translation, growth, proliferation, survival, autophagy, lipid biogenesis, cytoskeletal 
changes, angiogenesis).
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understanding mTOR complex function 
resides in our ability to merge upstream 
signaling flux into mTOR complex con-
trol of downstream substrates and cellular 
processes. While this may seem a daunt-
ing task, recent advances in genetic and 
proteomic technologies should permit a 
more detailed view of mTOR complex 
assembly and how these complexes are 
dynamically regulated to perform such 
intricate multitasking within the cell.
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differential RICTOR expression. In 
brainstem NSCs, there was significantly 
higher RICTOR expression relative to 
cortex NSCs (Fig. 6). These observations 
establish differential mTOR component 
expression as a primary determinant of 
cellular heterogeneity even in nearly iden-
tical cell types.
mTOR as a Dynamic Molecular 
Sensor and Integrator
In light of recent experimental obser-
vations on the central role of mTOR as 
a molecular sensor and integrator in a 
plethora of biological settings, the cur-
rent models of mTOR function require 
thoughtful re-examination. We propose 
a model in which the function of mTOR 
is dynamically regulated by spatially-, 
temporally- and signaling network-
defined conditions. In this regard, which 
molecules are physically assembled into 
the mTOR complex is dictated by their 
expression levels and activity status. Not 
only will differing levels of mTOR com-
ponent expression define the mTOR sig-
naling complex, but also the interplay of 
the signal transduction pathways acti-
vated at any given time within the cell. 
The activation of these pathways likely 
do not operate in a linear fashion, such 
that MEK activation not only affects 
tuberin phosphorylation to impact on 
mTOR signaling, but also on the activity 
and subcellular localization of other pro-
teins that define how mTOR signaling is 
regulated or the context in which its sig-
nals are transmitted. We view this state 
as the aggregate signaling flux (Fig. s7). 
In this setting, various mTORC compo-
nents are individually (on a molecule by 
molecule basis) modified at the protein 
level (through expression or modifica-
tion) to provide an overall landscape of 
mTOR-associated proteins. In effect, this 
provides the necessary complexity that 
allows mTOR to interpret a wide multi-
tude of input signals. Based on this land-
scape, mTORC1 and mTORC2 act to 
target select downstream effectors. Many 
of these targets control cellular processes 
specific to each mTOR complex but may 
be maintained by overlapping mTORC1 
and mTORC2 functions (e.g., mRNA 
translation). In any case, the key to 
phosphorylation, was elevated and could 
be ameliorated by rapamycin treatment. 
However, neither neurofibromin nor 
PTEN loss resulted in increased tuberin 
phosphorylation, suggesting that TSC 
inactivation was not involved. Consistent 
with a TSC-independent mechanism of 
mTOR activation, RHEB silencing using 
shRNA completely blocked mTOR acti-
vation in Tsc1-null astrocytes but had no 
effect on either mTOR activation or pro-
liferation in Nf1- or Pten-deficient cells. 
Since previous studies had shown that 
optic glioma growth in Nf1 genetically 
engineered mouse models could be inhib-
ited by rapamycin treatment,30 we hypoth-
esized that RAS activation, but not Tsc1 
loss or RHEB overexpression, in glial cells 
in vivo would result in gliomagenesis. In 
agreement with a model in which mTOR 
activation due to Tsc1 loss or RHEB over-
expression are not equivalent to neurofi-
bromin loss, Nf1 genetically engineered 
mice with glial Tsc1 loss or RHEB over-
expression did not develop optic glioma, 
whereas those with glial Ras activation 
did. While the precise mechanism under-
lying the differential activation of mTOR 
remains to be completely elucidated, these 
results support a model in which mTOR 
function is differentially dictated by the 
mode of mTOR activation by its upstream 
regulators.
Further functional support for mTOR 
heterogeneity dictating cell biology was 
provided by studies in which neural stem 
cells (NSCs) from two different regions of 
the mouse brain were analyzed.146 In these 
experiments, Nf1-deficient NSCs from 
the brainstem exhibited a cell autono-
mous increase in proliferation in vitro and 
increased gliogenesis in vivo, whereas NSCs 
from the neocortex did not (Fig. 6C). 
Examination of the signaling pathways 
deregulated following neurofibromin loss 
revealed that only brainstem NSCs had 
increased AKT activation. In contrast, 
no increase in AKT activity was observed 
in Nf1-/- cortex NSCs. Interestingly, the 
AKT hyperactivation and increased NSC 
proliferation was TORC2-dependent and 
could be blocked by rapamycin treatment 
or RICTOR genetic silencing but not by 
RAPTOR shRNA knockdown. The basis 
for this striking difference in both mTOR 
function and NSC biology reflected 
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